Poster Presentations

1500-1600 MONDAY AFTERNOON

AN INTERNATIONAL INTERLABORATORY QUALITY CONTROL (QC) PROGRAM FOR BIO-ANALYSIS OF TUBERCULOSIS DRUGS.
Aarnoutse R1,2, Robijns K2, Harteveld A2, Greijdanus B3, Uges D2,3, Touw D2, Alffenaar J.W.3 1 Dept. of Pharmacy, Radboud University Medical Centre, Nijmegen, The Netherlands, 2. KKGT: Association for Quality Assessment in TDM and Clinical Toxicology, The Hague, The Netherlands (www.KKGT.nl), 3. Dept. of Hospital and Clinical Pharmacy, University Medical Centre Groningen, Groningen, The Netherlands

WEIGHT STATUS AND THE EFFECT ON DOSING VANCOMYCIN IN PEDIATRIC PATIENTS.
Weston, A.S.1, Constance, J.E.1, Sherwin, C.M.T1, Campbell, S.C1, Stockmann, C.1, Mihalopoulos, N.L.2, Korgenski, E.K.3, Spigarelli, M.G.1,2 1Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah. 2Dept. of Pediatrics, Div. of Adolescent Medicine, University of Utah. 3Intermountain Healthcare, Pediatric Clinical Program, University of Utah

DETERMINATION OF AMIKACIN PHARMACOKINETIC PARAMETERS IN KUWAITI HOSPITALIZED PATIENTS.
Al-lanqawi Y1, Matar K2, Abudlmalek K3, Thusu A4, Jelliffe R5. 1Departments of Pharmacy – Drug and poison information & Research Unit, 3Intensive Care and 4Medicine, Al-Amiri Hospital, Ministry of Health, Kuwait; Department of 2Applied Therapeutics, Faculty of pharmacy -Kuwait University;5Laboratory of Applied Pharmacokinetics, School of Medicine, University of Southern California, LA, USA.

RATES OF OXYCODONE IN HAIR AND MECONIUM BEFORE AND AFTER THE RELEASE OF OXYNEO IN CANADA.
Carnevale, A1,2, Gareri, J1, Walasek, P1, Karaskov, T1, Koren, G1,2,3 1Motherisk Laboratory, The Hospital for Sick Children, Toronto, Canada; 2Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada; 3Ivey Chair in Molecular Toxicology, University of Western Ontario, London, Canada.

PROLONGED ELIMINATION TIME OF PALIPERIDONE AFTER ADMINISTRATION OF PALIPERIDONE PALMITATE DEPOT INJECTIONS.
Helland A1, Syrstad VEG2, Spigset O1,3. 1 Dept. of Clinical Pharmacology, St. Olav University Hospital, Trondheim, Norway. 2Division of Mental Health Care, St. Olav University Hospital, Trondheim, Norway. 3Dept. of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway.

IMPORTANCE OF THERAPEUTIC DRUG MONITORING (TDM) OF FLECAINIDE FOR PAROXYMAL SUPRAVENTRICULAR TACHYCARDIA IN CHILDREN IN THE FIRST YEAR OF LIFE.
Bartoli A.N.1, Mannarino, S2, Broglia M1 Codazzi A2, Magrassi S4, Stronati M3, Regazzi M1. 1Unit of Clinical and Experimental Pharmacokinetics, 2Pediatric Cardiology, Pediatric Department, 3Neonatal Intensive Care Unit Foundation IRCCS Policlinico San Matteo, Pavia, Italy. 4Pediatric Medical School University of Pavia, Italy.

INSUFFICIENT SERUM CASPOFUNGIN LEVELS IN A PAEDIATRIC PATIENT ON ECMO.
Koch BCP1, Wildschut ED2, Goede de AL1, Hoog de M2, Brüggemann RJM3
1Dept. Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands, 2Dept. Intensive Care Sophia’s Children’s Hospital, Erasmus MC, Rotterdam, the Netherlands, 3Clinical Pharmacy and Nijmegen Institute for Infection, Inflammation and Immunity, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

PHARMACOKINETICS OF VEMURAFENIB IN A PATIENT WITH METASTATIC MELANOMA AND RENAL FAILURE ON HEMODIALYSIS. A CASE REPORT
Broglia M1, Bartoli A.N.1, Valentino F2, Esposito P3, Montagna M1, Pedrazzoli P2. 1Unit of Clinical and Experimental Pharmacokinetics, 2Section of Oncology and 3Unit of Nephrology, Dialysis and Transplantation Foundation IRCCS Policlinico San Matteo, Pavia, Italy.

ANALYTICAL CHALLENGES IN DRIED BLOOD SPOT AND PLASMA SAMPLING FOR THERAPEUTIC DRUG MONITORING OF ANTIEPILEPTIC DRUGS.
Linder C, Andersson M, Mahindi M, Olof Beck, Pohanka A. Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University hospital and Karolinska Institute, Stockholm, Sweden.

PROOF OF CONCEPT: A PROTOTYPE ASSAY FOR HIGH SPEED IMATINIB QUANTITATION BY IMMUNOASSAY.
Baldasano CN, Jarrah J, Glass E, Courtney J, Cline DJ, Baburina I, Salamone SJ. Saladax Biomedical, Inc., Bethlehem, PA, USA.

LC-MS/MS OF ATYPICAL ANTIPSYCHOTICS IN DRIED BLOOD SPOTS.
Fisher DS, Partridge SJ, Flanagan RJ. Toxicology Unit, King’s College Hospital, London, UK.

POOR PERFORMANCE OF LABORATORIES ASSAYING NEWLY DEVELOPED ANTIRETROVIRAL AGENTS: RESULTS FOR DARUNAVIR, ETRAVIRINE AND RALTEGRAVIR FROM THE INTERNATIONAL QUALITY CONTROL PROGRAM FOR MEASUREMENT OF ANTIRETROVIRAL DRUGS IN PLASMA.
Burger D1, Krens S1, Robijns K2, Aarnoutse R1, Brüggemann R1, Touw D2. 1Department of Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. 2KKGT: Dutch Association for Quality Assessment in Therapeutic Drug Monitoring & Clinical Toxicology, The Hague, The Netherlands(www.kkgt.nl).

SPOTLIGHT ON THE PATTERN OF DRUG ABUSE AND THE MOST CONSUMED DRUGS FOR EGYPTIANS IN THE PERIOD 2007-2012.
EL Desoky ES, Hamdi MM, Farghaly HS, Abdelzaher LA, Hareedy MS, Taha AF, and Molla MS. Pharmacology Department, and drug monitoring and abuse lab, Assiut Faculty of Medicine and University Hospital, Assiut, Egypt.

THE EFFECT OF GESTATIONAL AGE ON THE INSULIN TO C-PEPTIDE RATIO IN NEONATES.
Salis E.R1, Reith D.M2, Broadbent R.S2, Wheeler B.J2, Medlicott N.J1. 1New Zealand’s National School of Pharmacy, University of Otago, Dunedin.2Dunedin School of Medicine, University of Otago, Dunedin.

INAPPROPRIATE RESPOND TO TREATMENT DUE TO DRUG INTERACTION BETWEEN VALPROIC ACID AND CARBAPENEMS.
Halacova M1, Ticha J.2, Hyanek T.3, Cerny, D.1, Gallusova, J.1. 1Department of Clinical Pharmacy, Hospital Homolka, Prague. 2Department of Clinical Biochemie, Hematology and Imunology, Hospital Homolka, Prague.3 Department of Anaesthesia and Intensive care, Hospital Homolka, Prague.

BREAST-FED INFANTS WHOSE, MOTHERS WERE ON PLATINUM BASED CHEMOTHERAPY: CASES WITH PROMISING OUTCOMES.
Tesfaye H1, Halaska M.J.2, Branova P1, Prusa R1, Rob L2, Skultety J2, Robova H2. 1Department of Medical Chemistry and Clinical Biochemistry, Division of Clinical Pharmacology. 2Department of Obstetrics and Gynecology, Faculty Hospital in Motol, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic.

IMPACT OF P-GLYCOPROTEIN AND BREAST CANCER RESISTANCE PROTEIN ON THE BRAIN DISTRIBUTION OF ANTIEPILEPTIC DRUGS.
Yano I1, Nakanishi H1, Yonezawa A2, Matsubara K2. 1Department of Clinical Pharmacy and Education, Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan. 2Department of Pharmacy, Kyoto University Hospital, Kyoto, Japan.

VANCOMYCIN REMOVAL DURING LOW-FLUX AND HIGH-FLUX EXTENDED DAILY HEMODIALYSIS IN CRITICALLY ILL SEPTIC PATIENTS.
Kacirova I1,2, Petejova N4, Duricova J1,2, Urbanek K3, Grundmann M2, Martinek A4, Brozmanova H1,2, Zahalkova J5,6. 1 Department of Clinical Pharmacology University Hospital Ostrava. 2Department of Clinical Pharmacology Faculty of Medicine University of Ostrava. 3Department of Pharmacology Faculty of Medicine Palacky University Olomouc and University Hospital Olomouc. 4Department of Internal Medicine Faculty of Medicine University of Ostrava and University Hospital Ostrava. 5Department of Internal Medicine University Hospital Olomouc and Faculty of Medicine Palacky University Olomouc. 6Stredomoravska nemocnicni Hospital Sternberk.

TDM OF AMINOGLYCOSIDE ANTIBIOTICS AND VANCOMYCIN AS AN INDICATOR OF THE QUALITY OF MEDICAL CARE IN UNIVERSITY HOSPITAL OSTRAVA -RESULTS OF THE 3-YEARS MONITORING.
Kacirova I1,2, Grundmann M2, Sistik P1. 1Department of Clinical Pharmacology University Hospital Ostrava and 2Department of Clinical Pharmacology Faculty of Medicine University of Ostrava.

THERAPEUTIC DRUG MONITORING OF ANTIEPILEPTIC DRUGS DURING PREGNANCY.
Ritchie JC1, Scott-Harrell P1, Ramsey C.H.1 and Lukacin R2. 1Emory University School of Medicine, Atlanta, Georgia, USA. 2 Chromsystems Instrument & Chemicals GmbH, Am Haag 12, 82166 Gräfelfing/Munich, Germany.

LMP1-CD40 MOUSE MODEL OF LYMPHOMA: A NEW MODEL TO EVALUATE THE LYMPHOMAGENESIS POTENTIAL OF IMMUNOSUPPRESSANTS.
Stojanova, J1,2, David A2,3, Feuillard J2,3,4, Zimber-Strobl U5, Marquet P1,2,4, Faumont N2,3. 1Inserm, UMR S-850, Limoges, France; 2Université de Limoges, France; 3CNRS UMR 7276, Limoges, France ; 4CHU de Limoges, France; 5Klinische Molekularbiologie und Tumorgenetik, Helmholtz Center, Munich, Germany.

DETERMINATION OF AN INITIAL DOSE OF GENTAMICIN: EVALUATION OF 5 NOMOGRAMS IN A KOREAN POPULATION.
Jieon Lee, Seonghae Yoon, MD, Donghoon Shin, MD, Kyoung Soo Lim, MD, PhD, In-Jin Jang, MD, PhD, Howard Lee, MD, PhD, Sang-Goo Shin, MD, PhD, Kyung-Sang Yu, MD, PhD. Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.

METHADONE PHARMACOKINETICS IN AN OBESE PATIENT.
Kapur, B. M. Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children and Department of Laboratory Medicine and Pathobiology, University of Toronto, and Canadian Medical laboratories, Mississauga, ON.

ASSOCIATION OF SERUM CYTOKINE PROFILES WITH TACROLIMUS-INDUCED CHRONIC NEPHROTOXICITY IN CHINESE LIVER TRANSPLANT RECIPIENTS.
Jiangtao Tang1, Yunying Shi2, Junlong Zhang1, Yi Li1, Yunfei An1, Lanlan Wang1*. 1Department of Laboratory Medicine, West China Hospital of Sichuan University, No. 37 Guoxue Road, Chengdu 610041, P. R. China. 2Department of Nephrology, West China Hospital of Sichuan University, No. 37 Guoxue Road, Chengdu 610041, P. R. China. *Corresponding author. Tel.: +86 28 85422751 Fax: +86 28 85422751, E-mail address: wanglanlan999@163.com

INFLUENCE OF CYP3A5, CYP2C8 AND ABCB1 POLYMORPHISMS ON TACROLIMUS-INDUCED NEPHROTOXICITY IN LIVER TRANSPLANT RECIPIENTS.
Yunying Shi2, Jiangtao Tang1, Junlong Zhang1, Yunfei An1, Yun Liao1 ,Yi Li1, Lanlan Wang1*. 1Department of Laboratory Medicine, West China Hospital of Sichuan University. Chengdu, Sichuan ,China. 2Department of nephrology, West China hospital of Sichuan University, Chengdu, Sichuan,China.
*Correspondence: Lanlan Wang, MD, PhD, Department of Laboratory Medicine,West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, P. R.China.Tel.:+86 028 85422751 Fax: +86 028 85422751 Email:wanglanlan999@163.com

DEVELOPMENT AND ASSESSMENT OF NEW HYDROGELS FOR NON-INVASIVE IONTOPHORETIC SKIN SAMPLING.
Nogueiras-Nieto L, Blyth A, Butcher E, Carter L, Harrison R and Delgado-Charro MB. Department of Pharmacy and Pharmacology, University of Bath, UK.

TDM IN CLINICAL LABORATORY – DRUG INTERACTIONS INVOLVING MOST OFTEN INDICATED FIRST- AND SECOND-GENERATION ANTICONVULSANTS. INCIDENCE OF ALCOHOL ABUSE IN THE GROUP OF PATIENTS TREATED FOR EPILEPSY.
Polok Rajska M1, Loucka P1, Minar J1, Horna A2. 1SPADIA LAB a.s., Ostrava (Czech Republic), 2RADANAL s.r.o., Pardubice (Czech Republic).

A COMPARISON OF TWO REGIMENS (EXTENDED VERSUS SHORT INFUSION) OF MEROPENEM IN AN INTENSIVE CARE UNIT.
Mathew SK1, Mathew BS1, Naik GS1, Gupta RP1, Subramani K.2, Jacob GG2, Fleming D.H1. 1Department of Pharmacology and Clinical Pharmacology, 2 Surgical Intensive Care Unit, division of Critical Care, Christian Medical College, Vellore 632 004, Tamil Nadu, India.

FREQUENCY OF VANCOMYCIN TARGET TROUGH ATTAINMENT FOR CUTANEOUS AND INVASIVE STAPHYLOCOCCAL INFECTIONS.
Linakis, M.W., Constance, J.E., Stockmann, C., Campbell, S.C., Sherwin, C.M.T., Spigarelli, M.G. Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah.

EFFECT OF CYCLOSPORINE A AND ITS METABOLITES ON DIURNAL BLOOD PRESSURE VARIABILITY.
Grundmann M1, Kacirova I1, 2, Halvova P2, Brozmanova H1,2. 1Department of Clinical Pharmacology Faculty of Medicine University of Ostrava and 2Department of Clinical Pharmacology University Hospital Ostrava.

ULTRAFAST QUANTITATIVE ANALYSIS OF SMALL MOLECULES IN SERUM AND URINE USING AN ONLINE SPE/MS/MS SYSTEM.
Youssef. M., Miller.V., LaMarr. W. Agilent Technologies, Wakefield, MA.

RELATIONSHIP BETWEEN BLOOD GLUCOSE LEVELS AND SERUM HEAVY AND TRACE METALS CONCENTRATIONS OF TYPE 2 DIABETICS AT THE OBAFEMI AWOLOWO UNIVERSITY TEACHING HOSPITAL COMPLEX, Ile-Ife.
Afolabi O. T M.B.Ch.B, M.P.H; Olawande O B.Sc. Biochemistry, M.P.H. Department of Community Health, College of Health Sciences, Obafemi Awolowo University, Ife, Nigeria.

APPLICATION OF DRUG TESTING USING EXHALED BREATH IN A CRIMINAL JUSTICE SETTING
Beck O, Stephanson N, Shafaati M, Sandqvist S. Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.

SEVERE DECREASE OF CYCLOSPORINE LEVELS IN A HEART TRANSPLANT RECIPIENT RECEIVING THE DIRECT THROMBIN INHIBITOR ARGATROBAN.
Sanchez R1, Picard N2, Mouly-Bandini A3, Collart F3, Lacarelle B1, Sampol-Manos E1.
1Phamacokinetic and toxicology department CHU timone Marseille France; 2Inserm, UMR-S850, Limoges, France; 3Cardiac surgery department CHU Timone, Marseille, France.

EVALUATION OF ASSAY TECHNIQUES FOR THE MEASUREMENTS OF AMIKACIN, GENTAMICIN AND VANCOMYCIN IN SERUM: RESULTS FROM THE BELGIAN EXTERNAL QUALITY ASSESSMENT SCHEME.
Delattre IK1, Soumali R1, Van de Walle P1, Wallemacq P2. 1Quality of Medical Laboratories, Scientific Institute of Public Health, Belgium. 2Laboratory of Toxicology and Therapeutic Drug Monitoring, Université catholique de Louvain, Saint-Luc Hospital, Belgium.

HOW APPROPRIATE IS THERAPEUTIC DRUG MONITORING FOR LITHIUM? DATA FROM THE BELGIAN EXTERNAL QUALITY ASSESSMENT SCHEME.
Delattre IK1, Coucke W1, Soumali R1, Van de Walle P1, Wallemacq P2. 1Quality of Medical Laboratories, Scientific Institute of Public Health, Belgium. 2Laboratory of Toxicology and Therapeutic Drug Monitoring, Université catholique de Louvain, Saint-Luc Hospital, Belgium.

ASSESSMENT OF THERAPEUTIC GUIDELINE ADHERENCE FOR VANCOMYCIN USE IN NEONATES
Firth, S.D.1, Yakub, S.Y.1, Sherwin, C.M.T.1, Korgenski, E.K.2, Constance, J.E.1, Balch, A.1, Spigarelli, M.G1. 1Dept. of Pediatrics, Div. of Clinical Pharmacology, University of Utah. 2Intermountain Healthcare, Pediatric Clinical Program, University of Utah.

STABILITY OF OLANZAPINE, N-DESMETHYLOLANZAPINE (NOROLANZAPINE) AND 2-HYDROXYMETHYLOLANZAPINE IN BIOLOGICAL SAMPLES.
Handley SA, Flanagan RJ. Toxicology Unit, King’s College Hospital, London, UK.

PLASMA OLANZAPINE, N-DESMETHYLOLANZAPINE (NOROLANZAPINE) AND 2-HYDROXYMETHYLOLANZAPINE CONCENTRATIONS IN PATIENTS PRESCRIBED OLANZAPINE.
Handley SA, Flanagan RJ. Toxicology Unit, King’s College Hospital, London, UK.

FATAL POISONING, ANTIPSYCHOTIC DRUGS, ENGLAND AND WALES, 2000–2011.
Handley SA, Flanagan RJ. Toxicology Unit, King’s College Hospital, London, UK.

EFFECT OF AGE AND GENDER ON CALCINEURIN INHIBITOR DRUG LEVELS DURING THE FIRST YEAR POST KIDNEY TRANSPLANTATION.
Turolo S1, Tirelli A2, Ghio L1, Belingheri M1, Ferraresso M3, Torresani E2, Edefonti A1. 1Pediatric Nephrology Unit, Ospedale Maggiore Policlinico Foundation, IRCCS, Milan, Italy; 2Laboratory of Clinical Pathology, Ospedale Maggiore Policlinico Foundation, IRCCS, Milan, Italy; 3Department of Clinical Sciences and Community Health, University of Milan Medical School, Milan, Italy.

DETECTION OF in utero DRUG EXPOSURE USING UMBILICAL CORD TISSUE AND LIQUID CHROMATOGRAPHY TIME-OF-FLIGHT MASS SPECTROMETRY (TOF).
Marin S.J.1, Metcalf A2, McMillin G.A.2,3. 1ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. 2ARUP Laboratories, Inc., Salt Lake City, UT. 3Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT.

CROSS VALIDATION OF THE THERMO FISHER QMS EVEROLIMUS THERAPEUTIC DRUG MONITORING ASSAY RUN ON FOUR DIFFERENT IMMUNOASSAY ANALYZER PLATFORMS WITH TEN GLOBAL LC-MS/MS LABORATORIES.
Christians, U1, Schniedewind, B, Billaud, E2, Poinsignon, V2. 1iC42 Clinical Research & Development, University of Colorado, Aurora, CO, USA; 2Université Paris Descartes Médecine, HEGP Pharmacologie, Paris, France.

CROSS-VALIDATION OF EVEROLIMUS LC-MS/MS AND THERMO FISHER QMS THERAPEUTIC DRUG MONITORING ASSAYS – THE ZORTRACKER CROSS-VALIDATION AND TDM SUPPORT PROGRAM.
Meyer EJ1, Schniedewind B2, Boucher R2, Johnson-Davis K.L.3, Galinkin J.L.2,4, Christians U2. 1Novartis Pharmaceutical Corp., East Hannover, NJ. USA; 2iC42 Clinical Research & Development, University of Colorado, Aurora, CO, USA; 3University of Utah/ARUP Laboratories, Salt Lake City, UT, USA; 4CPC Clinical Research, Aurora, CO, USA.

THERAPEUTIC DRUG MONITORING OF PSYCHOTROPIC DRUGS IN CHINA: A NATION-WIDE SURVEY.
Wei Guo1, Gui-xin Guo1, Chuan Sun1, Jun Zhang1, Zhang Rong1, Jing He1, Zuo-li Sun1, Fang Yan1, Yi-lang Tang1,2, Chuan-yue Wang1, Wen-biao Li,1*. 1Laboratory of Clinical Psychopharmacology, Beijing Key Lab of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China. 2Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

POPULATION PHARMACOKINETICS (popPK) OF CAPECITABINE IN ELDERLY PATIENTS WITH COLORECTAL OR BREAST CANCER.
Z. Daher Abdi1,2, S. Lavau-Denes3, F.L. Sauvage 1,5, S.Urien4, J. Martin3, S. Leobon3, Jb Woillard1, 2, P.Marquet1, 2,5, A. Rousseau1, 2, N. Tubiana-Mathieu3. 1Inserm, UMR-S850, Limoges, F-87025, France; 2Univ Limoges, F-87025, France; 3CHU Limoges, Service oncologie médicale, Limoges, F-87042, France ; 4EA 3620, Université Paris Descartes, Sorbonne Paris Cité, France; 5CHU Limoges, pharmacologie, toxicologie et pharmacovigilance, Limoges, F-87042, France.

EFFECTS OF ENTERAL NUTRITION ON THE ABSORPTION OF PHENYTOIN IN RATS.
Urashima Y12, Suzuki K2, Kurachi K2, Nishihara M2, Katsumata T2, Tanaka K3, Myotoku M1, Hirotani Y1. 1Laboratory of Clinical Pharmaceutics, Faculty of Pharmacy, Osaka Ohtani University, 3-11-1 Nishikiorikita Tondabayashi Osaka 584-8540, Japan. 2Department of Pharmacy, Osaka Medical College Hospital, 2-7 Daigakumachi Takatsuki Osaka 569-8686, Japan. 3Shirasagi Hospital, 7-11-23 Kumata Higashisumiyoshi-ku Osaka 546-0002, Japan.

INCREASED VANCOMYCIN DOSE SHOULD BE CONSIDERED FOR SEPTIC PATIENTS WITHOUT RENAL DYSFUNCTION: IMPORTANCE OF TDM-BASED DOSE ADJUSTMENT IN AN INTENSIVE CARE UNIT.
Yuko Shimamoto, BS1,2, Tsuyoshi Fukuda, PhD3, Kazuhiko Tanaka, MD4, Katsuya Komori, BS2, Daikai Sadamitsu, MD5. 1Department of Pharmacy, National Cerebral and Cardiovascular Center, Osaka, Japan; 2Department of Pharmacy, National Hospital Organization Osaka National Hospital, Osaka, Japan; 3Division of Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center & Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA; 4Kidney Center, Shirasagi Hospital, Osaka, Japan; 5Department of Traumatology & Critical Care Medical Center, National Hospital Organization Osaka National Hospital, Osaka, Japan.

1500-1600 WEDNESDAY AFTERNOON

MEDICATION EXPOSURES DURING PREGNANCY AND BREASTFEEDING.
Green, A1, Campbell, S.C.1, Thomas, K2, Sherwin, C.M.T.1, Spigarelli, M.G.1. 1Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA. 2Utah Poison Control Center, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA..

FEASIBILITY OF FOLLOWING UP GAMMA-HYDROXYBUTYRIC ACID CONCENTRATIONS IN SODIUM OXYBATE (Xyrem®)-TREATED NARCOLEPTIC PATIENTS USING DRIED BLOOD SPOT SAMPLING AT HOME: AN EXPLORATORY STUDY.
Ingels AS1*, Hertegonne K2, Lambert W 1, Stove C1. 1Laboratory of Toxicology, Ghent University, Harelbekestraat 72, 9000 Ghent, Belgium; 2Department for Respiratory Diseases, Center for Sleep Disorders, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium; *Current address: Federal Public Service Justice, National Institute of Criminalistics and Criminology, Vilvoordsesteenweg 100, 1120 Brussels, Belgium. Email:christophe.stove@ugent.be.

DEVELOPMENT OF LIMITED SAMPLING STRATEGY FOR MYCOPHENOLIC ACID: INFLUENCE OF POST-TRANSPLANT PERIOD AND SECOND PEAK.
Chaabane A1, Ben Fredj N1, Chadly Z1, Hammouda M2, El May M2, Boughattas NA1, Skhiri H2, Aouam K1. 1Pharmacology Laboratory. Faculty of Medicine of Monastir. University of Monastir. 2Nephrology Department. University Hospital of Monastir. University of Monastir.

DEVELOPMENT OF LIMITED SAMPLING STRATEGIES FOR TACROLIMUS ACCORDING TO THE POST-TRANSPLANT PERIOD.
Aouam K1, Chadly Z1, Chaabane A1, Ben Fredj N1, Hammouda M2, El May M2, Boughattas NA1, Skhiri H2.1Pharmacology Laboratory. Faculty of Medicine of Monastir. University of Monastir. 2Nephrology Department. University Hospital of Monastir. University of Monastir.

EFFECT OF ANGIOTENSIN II RECEPTOR BLOCKERS ON FORMATION OF EPOXYEICOSATRIENOIC ACIDS FROM ARACHIDONIC ACID VIA P450(CYP)2C9 AND CYP2C8.
Senda A1, Toda T1, Hayakawa T1, Inotsume N1, Rane A2, Eliasson E2. 1Hokkaido Pharmaceutical University School of Pharmacy; 2Karolinska Institutet.

THE EFFECTS OF OCCUPATIONAL ENVIRONMENT EXPOSURE ON ORGAN FUNCTIONS, EXPRESSION OF CYTOKERATIN – 19 FRAGMENTS (CYFRA 21 -1 PROTEIN) AND RISK OF LUNG CANCER IN SOME WELDERS.
Bosun Banjoko1*, Olusoji Ige2, Olufunso Olorunsogo3. 1Department of Chemical Pathology, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria. 2Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria. 3Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria. *Correspondence: bosunbanjoko@yahoo.com

PUBLISHED THERAPEUTIC DRUG MONITORING STUDIES: WHO IS SUPPORTING RESEARCH?
Stockmann, C., Sherwin, C.M.T., Spigarelli, M.G. Department of Pediatrics, Division of Clinical Pharmacology, University of Utah.

EFFECT OF IMMUNOSUPPRESSION WITH TACROLIMUS (Tac), MYCOPHENOLATE SODIUM (MPS), AND STEROIDS ON INFLAMMATION AND OXIDATIVE STRESS IN KIDNEY TRANSPLANT RECIPIENTS (KTR) WITH METABOLIC SYNDROME (MS).
Wieland E, Häfner S, Kabakchiev M, Shipkova M, Effenberger-Klein A, Olbricht CJ, Lobmann R. Klinikum Stuttgart, Germany

STUDY OF LEUCIN-RICH REPEAT KINASE 2 (LRRK2) G2019S MUTATION IN EGYPTIAN PATIENTS WITH PARKINSONISM
EL Desoky ES1*, Khedr EM2*, Khalil MS3*, and Gasser T4. 1Pharmacology, 2neurology and 3clinical pathology departments, Assiut Faculty of Medicine and University Hospital , Assiut, Egypt*. 4Hertie Institute for Clinical Brain Research Department of Neurodegenerative Diseases, Tübingen, Germany.

CYP2D6 AND ADJUVANT TAMOXIFEN: POSSIBLE DIFFERENCES IN OUTCOME FOR PRE- AND POSTMENOPAUSAL PATIENTS.
Margolin S1, Lindh JD2, Thorén L1, Xie H-J1, Koukel L2, Dahl M-L2, Eliasson E2. Karolinska Institutet, 1Department of Oncology & Pathology, 2Department of Laboratory Medicine, Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.

NEW ANALYSIS METHOD FOR PHOSPHATIDYLETHANOL 16:0/18:1 FROM WHOLE BLOOD BY UPLC-MS/MS.
Shafaati M1, Hedman E1, Helander A2, Beck O1. 1Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden. 2Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.

EARLY TACROLIMUS DOSING IN PEDIATRIC LIVER TRANSPLANTATION DEPENDS ON RECIPIENT CYP3A5 AND ABCB1 (OR MDR1) GENOTYPES: EXPERIENCE IN LIVING DONOR RECIPIENTS.
Guy-Viterbo V1, Panain N1, Janssen M2, Elens L1, Reding R2, Haufroid V1, Wallemacq P1. 1Louvain center for Toxicology & Applied Pharmacology (LTAP), Université Catholique de Louvain, Brussels, Belgium. 2Pediatric surgery and transplantation unit, Cliniques Universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium.

USEFULNESS OF ONE-POINT PLASMA SN-38G/SN-38 CONCENTRATION RATIOS AS A SUBSTITUTE FOR UGT1A1 GENETIC INFORMATION AFTER IRINOTECAN ADMINISTRATION
H. Takada1, K. Hirose1, K. Yamashita1, N. Kaneda1, K. Fukami1, E. Maruo1, M. Kitamura1, J. Hasegawa2, Y. Maeda1
1Department of Pharmacy, Osaka Rosai Hospital. 2Department of Surgery, Osaka Rosai Hospital.

POPULATION PHARMACODYNAMIC ANALYSIS OF HMG-COA REDUCTASE INHIBITORS (STATINS) IN JAPANESE ADULT PATIENTS BASED ON THE IN-HOSPITAL MEDICAL RECORDS
Nomura H1, Kakara M2, Yamasaki T2, Fukae M2, Hirota T2, Hirakawa M1, Ieiri I2. 1Department of Hospital Pharmacy, Fukuoka Tokushukai Medical Center, Fukuoka, Japan; 2Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

POPULATION PHARMACOKINETICS AND BAYESIAN ESTIMATION OF MELPHALAN CONCENTRATIONS IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION.
Mizuno K1, Dong M1, Fukuda T1,2, Anaissie E.J.3, Vinks A.A.1,2. 1Division of Clinical Pharmacology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA. 2Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA. 3University of Cincinnati Cancer Institute, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.

USEFULNESS OF JAPANESE EGFR IN PHARMACOKINETIC ANALYSIS OF AMIKACIN.
Shinozaki K1,3, Yamamoto M1, Tanaka J1, Kobayashi Y2, Saito M2. 1Pharmacokinetic Laboratory, Department of Clinical Pharmacy, Center for Clinical Pharmacy and Sciences, School of Pharmacy, Kitasato University, Tokyo, Japan. 2Department of Pharmacy, Kitasato Institute Hospital, Tokyo, Japan. 3Division of TDM, Kitasato Institute Hospital, Tokyo, Japan.

IMPACT OF POR*28 ON THE PHARMACOKINETICS OF TACROLIMUS AND CYCLOSPORINE A IN RENAL TRANSPLANT PATIENTS.
Laure Elens1,3, Dennis A. Hesselink2, Rachida Bouamar4, Klemens Budde5, Johannes W. de Fijter6, Dirk R.J. Kuypers7, Vincent Haufroid3, Teun van Gelder2,4, Ron H.N. van Schaik1. 1Departments of Clinical Chemistry, 2Internal Medicine, 4Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands, 3Louvain centre for Toxicology and Applied Pharmacology (LTAP), Université catholique de Louvain, Brussels, Belgium, 5Dept. Nephrology, Charite University, Berlin, Germany, 6Dept. Nephrology, Leiden University Medical Centre, Leiden, The Netherlands, 7Dept. Nephrology, University of Leuven, Leuven, Belgium.

A POTENTIAL PROTEOMIC BIOMARKER OF LOVASTATIN-INDUCED MACROPHAGE TOXICITY.
L. Zhang, X. Zhou, and A. Zhou. Cleveland State University, Cleveland, OH 44115.

ENDOXIFEN LEVELS ASSOCIATED TO CYP2D6 PHENOTYPE.
Antunes MV, Santos TV, Andreolla H, Rosa DD, Linden R. Universidade Feevale, Novo Hamburgo – RS, Brazil.

CYP2D6 PHENOTYPING BY HPLC-FL DETERMINATION OF DEXTROMETHORPHAN AND DEXTRORPHAN IN HUMAN PLASMA.
Antunes MV, Santos TV, Andreolla H, Rosa DD, Linden R. Universidade Feevale, Novo Hamburgo – RS, Brasil.

THERAPEUTIC POTENTIAL OF THE NAT2 GENOTYPE-GUIDED DOSING STRATIFICATION OF ISONIAZID IN CHEMOTHERAPY FOR TUBERCULOSIS.
Ohno M1,2, Azuma J1,2, Yokota S3, and Pharmacogenetics-based tuberculosis therapy research group. 1Hyogo University of Health Sciences. 2Graduate School of Pharmaceutical Sciences, Osaka University. 3National Hospital Organization Toneyama National Hospital, Japan.

SUICIDE AND HOMICIDE BY Para-phenylenediamine POISONING IN UPPER EGYPT.
Maha A. Hilal1, Khaled M. Mohamed2, Nady S. Aly2. 1Forensic Medicine and Clinical Toxicology Department, Faculty of Medicine, Sohag University, Egypt. 2Assiut Chemical Laboratory, Medico-Legal Department, Ministry of Justice, Egypt.

A STUDY ON THE ASSOCIATION OF HLA-B*1502 AND SEVERE CUTANEOUS ADVERSE DRUG REACTIONS INDUCED BY AROMATIC AMINE ANTI-EPILEPTIC DRUGS IN INDIAN PATIENTS: AN INTERIM REPORT.
Naik GS1, Vijayakumar TS2, Krishnan M2, Mathew SK1, Fleming DH1, Thomas M3, George R4.1Department of Pharmacology and Clinical Pharmacology, Christian Medical College, Vellore, 632 004, Tamil Nadu, India. 2Molecular Laboratory, Department of Nephrology, Christian Medical College, Vellore, 632 004, Tamil Nadu, India. 3Department of Neurology, Christian Medical College, Vellore, 632 004, Tamil Nadu, India. 4Department of Dermatology, Christian Medical College, Vellore, 632 004, Tamil Nadu, India.

CONVERSION FROM TWICE-DAILY TO ONCE-DAILY TACROLIMUS FORMULATION DOES NOT REDUCE INTRA-PATIENT VARIABILITY IN TACROLIMUS EXPOSURE
Shuker N1, van Gelder T1,2, Cadogan M2, Weimar W2, Hesselink D.A.2. Departments of 1Hospital Pharmacy, Clinical Pharmacology Unit and 2Internal Medicine, Division of Nephrology and Renal Transplantation, Erasmus MC, University Medical Center Rotterdam, the Netherlands.

IMPACT OF EVEROLIMUS ON IL-12, IL10, IL17 AND IFN-γ PRODUCTION: BALANCE BETWEEN EFFECTOR AND INFLAMMATORY RESPONSES IN LIVER TRANSPLANT RECIPIENTS.
O Millán1, Z. Mariño2, G. Crespo2, M. Navasa2, M. Brunet1. 1Pharmacology and Toxicology Laboratory (CDB), CIBERehd, IDIBAPS, Hospital Clínic de Barcelona. 2Liver Transplant Unit, CIBERehd, IDIBAPS; Hospital Clínic de Barcelona.

INFLUENCE OF GENETIC POLYMORPHISMS IN PATIENTS TREATED WITH NON-STANDARD TACROLIMUS DOSE REQUIREMENTS.
Outeda-Macías M, Salvador-Garrido P, Martínez-López LM, Cachafeiro-Pin AI, Martín-Herranz I. Pharmacy Service, University Hospital of A Coruña. Xerencia de Xestión Integrada A Coruña. A Coruña, Spain.

ROLE OF CYP2C9 AND VKORC1 POLYMORPHISMS IN PATIENTS WITH HYPERSENSITIVITY TO ACENOCOUMAROL.
Outeda-Macías M, Salvador-Garrido P, Martínez-López LM, Sánchez-Parada L, Martín-Herranz I. Pharmacy Service, University Hospital of A Coruña. Xerencia de Xestión Integrada A Coruña. A Coruña, Spain.

DETECTION OF OUTLIERS AND ACCURACY OF PHARMACOKINETIC PARAMETER ESTIMATION USING PARAMETRIC AND NON PARAMETRIC POPULATION MODELING APPROACHES.
Caceres Guido P.1, Neely M. N.2, Niselman V.3, Schaiquevich P.1,4. 1Clinical Pharmacokinetics Unit, Hospital de Pediatria JP Garrahan, Buenos Aires, Argentina. 2Laboratory of Applied Pharmacokinetics, University of Southern California and Children’s Hospital Los Angeles, Los Angeles, CA, United States of America. 3Mathematics, Faculty of Pharmacy and Biochemistry, University of Buenos Aires. 4CONICET.

CLINICAL PHARMACOKINETICS OF MELPHALAN AFTER SUPER-SELECTIVE OPHTHALMIC ARTERY INFUSION IN RETINOBLASTOMA PATIENTS.
Schaiquevich P1,5, Taich P1, Buitrago E1, Ceciliano A2, Villasante F2, Fandiño A3, Chantada G4. 1Clinical Pharmacokinetics Unit, Hospital de Pediatria JP Garrahan. 2 Swiss Argentine Clinic and Maternity. 3,4Services of Ophtahlmology and Hematology-Oncology, Hospital JP Garrahan, Argentina. 5CONICET.

GENETIC DATABASES AND THEIR PITFALLS: AN EXAMPLE RELATED TO PHARMACOGENETICS.
Pouché L1,2,3, Avcu K3, Esperon P4, Noceti O1,2,4, Marquet P1,2,3, Picard N1,2,3. 1Inserm, UMR S-850, Limoges, France. 2Univ. Limoges; 3CHU Limoges, Department of Pharmacology and Toxicology, 4Molecular Biology Unit, Clinical Biochemistry Department , Faculty of Chemistry, University of the Republic, Montevideo, Uruguay.

SIMULTANEOUS DETERMINATION OF LAMOTRIGINE, 10-HYDROXY-CARBAMAZEPINE, PHENOBARBITAL, CARBAMAZEPINE-10,11-EPOXIDE, PHENYTOIN AND CARBAMAZEPINE IN DRIED BLOOD SPOTS BY HPLC-DAD.
Lima GMS, Rhoden L, Silva CA, Rama C, Linden, R. Universidade Feevale, Novo Hamburgo, Brazil.

ROPIVACAINE CONCENTRATIONS (TOTAL AND UNBOUND) FOLLOWING TRANSVERSE ABDOMINIS PLANE (TAP) BLOCK FOR ANALGESIA FOLLOWING ABDOMINAL SURGERY – A PILOT STUDY.
Morris RG1,2, Kumar S3, Watts R3, Rao V3, Westley IS1. 1Department of Cardiol & Clin Pharmacol, The Queen Elizabeth Hospital, Woodville, SA; 2Discipline of Pharmacol, The University of Adelaide. Adelaide, SA; 3Department of Anaesthesia, The Queen Elizabeth Hospital, Woodville, SA.

THIOPURINE METHYLTRANSFERASE PHARMACOGENOMIC TESTING: KNOWN BUT INFREQUENTLY DONE.
Campbell, S.C.1, McMillin, G2, Sherwin, C.M.T.1, Spigarelli, M.G.1. 1Department of Pediatrics, Division of Clinical Pharmacology, University of Utah. 2Department of Pathology and ARUP Laboratories, University of Utah.

THE EFFECT OF AGE ON A BIOMARKER OF ACETAMINOPHEN-INDUCED HEPATOTOXICITY.
Cook SF1,2, Parker AD1, Hathaway LB2, McGill LD3, Franklin MR2, Wilkins DG1,2, Rollins DE1,2. 1Center for Human Toxicology, University of Utah, Salt Lake City, UT. 2Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT. 3Associated Regional and University Pathologists, Inc., Salt Lake City, UT.

PHARMACOKINETICS OF MORPHINE DURING PATIENT-CONTROLLED ANALGESIA (PCA) IN POST-OPERATIVE PAIN RELIEF.
De Gregori S1, Niebel T2, Bugada D2, Regazzi M1. 1Clinical and Experimental Pharmacokinetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia. 2Pain Therapy Service, Fondazione IRCCS Policlinico San Matteo, Pavia.

INVESTIGATION OF QUETIAPINE PHARMACOKINETICS AND ITS CORRELATION WITH CYP3A5 OR MDR1 POLYMORPHISMS: A POPULATION PHARMACOKINETIC APPROACH.
Sireen Shilbayeh, PhD1, Melhem, PhD2, Rawan Zmeili, MSc3. 1Clinical Pharmacy Department, Pharmacy College, Princess Nora University, Riyadh, Kingdom of Saudi Arabia. 2Institute for Clinical Pharmacodynamics, Latham, NY, USA. 3ICU Clinical Pharmacy Services, King Saud Medical City, Riyadh, Kingdom of Saudi Arabia.

POPULATION PHARMACOKINETICS OF CAFFEINE IN NEONATES TO IMPROVE THERAPEUTIC RANGE ATTAINMENT.
Yu, T., Sherwin, C.M.T., Balch, A., Spigarelli, M.G. Department of Pediatrics, Div. of Clinical Pharmacology, University of Utah.

CHARACTERISTICS AND TRENDS OF VANCOMYCIN CLINICAL TRIALS REGISTERED IN THE UNITED STATES FROM 1997-2012.
Yu, T., Stockmann C., Balch A., Sherwin C.M.T., Spigarelli M.G. Division of Clinical Pharmacology, Department of Pediatrics, University of Utah.

THE ELEVATION OF PLASMA CREATINE PHOSPHOKINASE LEVEL INDUCED BY DAPTOMYCIN: A CASE REPORT.
Tomoyuki Yamada1,2, Kaoru Suzuki1, Yukimasa Ooi2,3, Fumiko Kawanishi2, Yuriko Shibata2, Takashi Nakano2,4, Masami Nishihara1, Takahiro Katsumata1, Akira Ukimura2,3. 1Department of pharmacy, Osaka Medical College Hospital.2Infection control center, Osaka Medical College Hospital. 3Department of general internal medicine, Osaka Medical College. 4Department of microbiology and infection control, Osaka Medical College.

POTENTIAL APPLICATION OF GAMMA-HYDROXYBUTYRIC ACID GLUCURONIDE IN URINE AS A BIOMARKER FOR GHB INTOXICATION.
Breindahl T1, Eriksen K.K.2, Møller K3, Skanning P.G 3. 1Department of Clinical Biochemistry, Vendsyssel Hospital, Aalborg University, Denmark. 2Department of Clinical Biochemistry, Bispebjerg Hospital, Denmark. 3Department of Anesthesiology Z, Bispebjerg Hospital, Denmark.

CAUSES OF VARIABILITY IN DETERIORATION OF RENAL FUNCTION AMONG PEDIATRIC LIVER TRANSPLANT RECIPIENTS RECEIVING TACROLIMUS.
Gijsen V.M.G.J.1,2, Hesselink D. A.3, ‘t Jong G.W.2, van Schaik R.H.N.4, Ng V.5, Grant D.6, Feroz Zada Y.7, Nasserinejad K.8, van Rosmalen J.8, Verjee Z.9, Ross C.10, Carleton B.10, Hayden M.R.11, Tibboel D.1, Dubé M-P7,12, Koren G.2,13, de Wildt S.N.1. 1Intensive Care and Department of Paediatric Surgery, Erasmus MC Sophia Children’s Hospital, Rotterdam, the Netherlands. 2Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada. 3Department of Internal Medicine, Division of Nephrology and Renal Transplantation, Erasmus MC, Rotterdam, the Netherlands. 4Department of Clinical Chemistry, Erasmus MC, Rotterdam, the Netherlands. 5Division of Gastroenterology and Nutrition, Department of Pediatrics, The Hospital for Sick Children, Toronto, Ontario, Canada. 6Multi-Organ Transplant Program, University of Toronto, Toronto, Ontario, Canada. 7Université de Montréal, Department of Medicine, Montréal, Quebec, Canada. 8Department of Biostatistics, Erasmus MC, Rotterdam, the Netherlands. 9Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, Canada and Assistant Professor, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. 10Department of Paediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. 11Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada. 12Montréal Heart Institute Research Centre, Montréal, Quebec, Canada. 13Ivey Chair in Molecular Toxicology, Department of Medicine, University of Western Ontario, London, ON, Canada.

GENETIC VARIATION DOES NOT INFLUENCE RENAL FUNCTION FOLLOWING PEDIATRIC KIDNEY TRANSPLANTATION RECEIVING TACROLIMUS.
Gijsen V.M.G.J.1,2, Hesselink D.A.3, Ross C.4, Dubé M-P.5,6, van Schaik R.H.N.7, Van Gelder T.3,8, Cransberg K.9, ‘t Jong G.W.2, Feroz-Zada Y.5, Nasserinejad K.10, van Rosmalen J.10, Hebert D.11, Grant D.12, Verjee Z.13, Carlton B.4, Hayden M.R.14, Tibboel D.1, de Wildt S.N.1, Koren G.2,15. 1 Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children’s Hospital, Rotterdam, the Netherlands. 2Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada. 3Department of Internal Medicine, Division of Nephrology and Renal Transplantation, Erasmus MC, Rotterdam, the Netherlands. 4Department of Pediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. 5Montréal Heart Institute Research Centre, Montréal, Quebec, Canada. 6Université de Montréal, Department of Medicine, Montréal, Quebec, Canada. 7Department of Clinical Chemistry, Erasmus MC, Rotterdam, the Netherlands. 8Hospital Pharmacy, Erasmus MC, Rotterdam, the Netherlands. 9Department of Pediatric Nephrology, Erasmus MC Sophia Children’s Hospital, Rotterdam, the Netherlands. 10Department of Biostatistics, Erasmus MC, Rotterdam, the Netherlands. 11Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada. 12Multi-Organ Transplant Program, University of Toronto, Toronto, Ontario, Canada. 13Department of Laboratory Medicine and Pathobiology, The Hospital for Sick Children, Toronto, Ontario, Canada. 14Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada. 15Ivey Chair in Molecular Toxicology, Department of Medicine, University of Western Ontario, London, ON, Canada.

INVESTIGATING GENETIC AND CLINICAL SOURCES OF VARIABILITY IN PREDICTING DETERIORATION OF RENAL FUNCTION AMONG PEDIATRIC HEART TRANSPLANT RECIPIENTS RECEIVING TACROLIMUS.
Gijsen V.M.G.J.1,2, Dubé M-P3,4, Hesselink D.A.5, Ross C.6, Mital S.7, ‘t Jong G.W.2, van Schaik R.H.N8, Dalinghaus M.9, Grant D.10, Feroz Zada Y.4, Nasserinejad K.11, van Rosmalen J.11, Verjee Z.12, Carleton B.6, Hayden M.R.13, Tibboel D.1, Koren G.2,14, de Wildt S.N.1. 1Intensive Care and Department of Pediatric Surgery, Erasmus MC Sophia Children’s Hospital, Rotterdam, the Netherlands. 2Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, Toronto, Ontario, Canada. 3Montréal Heart Institute Research Centre, Montréal, Quebec, Canada. 4Université de Montréal, Department of Medicine, Montréal, Quebec, Canada. 5Department of Internal Medicine, Division of Nephrology and Renal Transplantation, Erasmus MC, Rotterdam, the Netherlands. 6Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, University of British Columbia, Vancouver, Canada. 7Division of Cardiology, Hospital for Sick Children, Toronto, Ontario, Canada. 8Department of Clinical Chemistry, Erasmus MC, Rotterdam, the Netherlands. 9Pediatric Cardiology, Erasmus MC Sophia Children’s Hospital, Rotterdam, the Netherlands. 10Multi-Organ Transplant Program, University of Toronto, Toronto, Ontario, Canada. 11Department of Biostatistics, Erasmus MC, Rotterdam, the Netherlands. 12Department of Laboratory Medicine and Pathobiology, The Hospital for Sick Children, Toronto, Ontario, Canada. 13Department of Paediatrics, Division of Translational Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada. 14Ivey Chair in Molecular Toxicology, Department of Medicine, University of Western Ontario, London, ON, Canada.

HOW TO HANDLE WITH TIME-DEPENDENT METHOTREXATE ELIMINATION: A MODELING APPROACH.
Woillard JB1,2, Debord J1,2, Neely M3, Marquet P1,2, Saint-Marcoux F1,2. 1Pharmacology Department, CHU Limoges, France. 2INSERM UMR-S850, Univ Limoges, France. 3Laboratory of Applied Pharmacokinetics, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.

SIGNIFICANT INCREASE IN PLASMA 4Β-HYDROXYCHOLESTEROL CONCENTRATION AS AN ENDOGENOUS MARKER OF CYP3A ACTIVITY IN PATIENTS WITH END STAGE RENAL DISEASE AFTER KIDNEY TRANSPLANTATION
Suzuki Y1, Itoh H1, Sato F2, Kawasaki K1, Sato Y1, Fujioka T1, Sato Y1, Ohno K3, Mimata H2, Kishino S3. 1Department of Clinical Pharmacy, Oita University Hospital, Hasama-machi, Oita 879-5593, Japan. 2Department of Urology, Faculty of Medicine, Oita University, Hasama-machi, Oita 879-5593, Japan. 3Department of Medication Use Analysis and Clinical Research, Meiji Pharmaceutical University, Kiyose, Tokyo 204-8588, Japan.

POISON CONTROL CENTER CALLS REGARDING PREGNANT AND BREASTFEEDING WOMEN.
Bridges, Z.M., Campbell, S.C., Thomas, K.C., Sherwin, C.M.T., Spigarelli, M.G. Department of Pediatrics, Division of Clinical Pharmacology, University of Utah.

ASSESSMENT OF ABUSE DRUGS IN EMERGENCY HOSPITAL, MANSOURA UNIVERSITY, EGYPT.
R.A. Mandour1*, A.A. Ghanem2. 1Toxicology Unit, Emergency Hospital, Mansoura University, Egypt. 2Forensic Med. and Clin. Toxic. Department, Faculty of Medicine, Mansoura University, Egypt. *Correspondence: mandourraafat@yahoo.com, 0020125260108.

TPMT ALLELIC VARIANTS IN PATIENTS ON THIOPURINE THERAPY.
Raghavan R.1, Shah S.1, Bhawalkar S.1, Desai D.2, Kapadia A.3, Almel S.3, Ashavaid T.F.1. 1Department of Laboratory Medicine, P.D.Hinduja National Hospital & MRC, Mumbai, India. Department of Gastroenterology, P.D.Hinduja National Hospital & MRC, Mumbai, India. 3Department of Oncology, P.D.Hinduja National Hospital & MRC, Mumbai, India.

1330-1430 THRUSDAY AFTERNOON

PERFORMANCE CHARACTERISTICS OF THREE ASSAYS FOR THE THERAPEUTIC DRUG MONITORING OF METHOTREXATE.
Suh-Lailam B1, Juenke J2, Thompson C3, Wilson L3, Johnson-Davis K1,2. 1Department of Pathology, University of Utah, Salt Lake City, 84112. 2ARUP Institute of Clinical and Experimental Pathology, Salt Lake City, Utah 84108. 3ARUP Laboratories, Salt Lake City, Utah 84108.

THE QMS® TACROLIMUS ASSAY ON THE ROCHE COBAS® 6000 C501 ANALYZER – COMPARISON TO LCMS/MS.
Shalapay C, LeGatt D. Department of Laboratory Medicine and Pathology, University of Alberta Hospital, Alberta Health Services, Edmonton, Canada.

DEVELOPMENT AND VALIDATION OF A MATRIX-MATCHED ASSAY TO MEASURE IODINE IN SERUM BY INDUCTIVELY COUPLED PLASMA-MASS SPECTROMETRY.
Haglock C.J.1, Strathmann F.G.1,2. 1ARUP Laboratories, Salt Lake City, UT; 2ARUP Institute for Clinical and Experimental Pathology, and Department of Pathology, University of Utah, Salt Lake City, UT.

PRECISION AND ACCURACY PERFORMANCE EVALUATION OF THE ELECSYS TACROLIMUS AND CYCLOSPORINE A ASSAYS.
Shipkova M.1, Verstraete A.2, Wallemacq P.3, Vogeser M.4, Alìa P.5, Widmann M.6, Schneider-Thauern C.6. 1Katharinenhospital Stuttgart, Germany; 2Gent University Hospital, Belgium; 3Clinique Universitaire St. Luc, Belgium; 4Klinikum der Universität München, LMU, Germany; 5Hospital Universitari de Bellvitge, Spain; 6Roche Diagnostics GmbH Mannheim, Germany.

METHOD COMPARISON STUDY OF THE ELECSYS TACROLIMUS ASSAY WITH LC-MS/MS, ABBOTT ARCHITECT AND SIEMENS DIMENSION AS COMPARATORS.
Wallemacq, P.1, Shipkova M.2, Verstraete A.3, Vogeser M.4, Alía P.5, Schneider-Thauern C.6 1Clinique Universitaire St. Luc, Belgium; 2Katharinenhospital, Stuttgart, Germany; 3Gent University Hospital, Belgium; 4Klinikum der Universität München, LMU, Germany; 5Hospital Universitari de Bellvitge, Spain; 6Roche Diagnostics GmbH Mannheim, Germany.

QMS® TEICOPLANIN IMMUNOASSAY: AN IMMUNOASSAY FOR THE QUANTITATIVE DETERMINATION OF TEICOPLANIN
Cheung C, Arabshahi L, Li H. Clinical Diagnostics Division, Thermo Fisher Scientific, Fremont, CA, USA.

ULTRA HIGH THROUGHPUT ANALYSIS OF IMMUNOSUPPRESSANTS IN WHOLE BLOOD BY MICROFLOW LC-MS/MS.
Blake, D; Jarvis M.

DETERMINARION OF ANAGRELIDE IN HUMAN PLASMA BY A VALIDATED LC-MS/MS METHOD.
Svinarov D, Kasabova L, Kostova K. Central Laboratory of Therapeutic Drug Management and Clinical Pharmacology, Alexander University Hospital, Faculty of Medicine, Medical University, Sofia, Bulgaria.

A NEWLY DEVELOPED UPLC/MS/MS CLINICAL RESEARCH METHOD FOR THE ANALYSIS OF METHOTREXATE IN SERUM WAS COMPARED WITH TWO IMMUNOASSAYS.
Cooper DP1, Eastwood MP1, Monaghan PJ2, Thomson Y2, Calton LJ1. 1Waters Corporation, Atlas Park, Manchester, M22 5PP, UK. 2The Christie Hospital NHS Foundation Trust, Manchester, M20 4BX, UK.

AN OLD-FASHIONED LOVE SONG: HARMONIZATION OF ROUTINE TACROLIMUS MEASUREMENTS BY LC-MS
Mason D1, Annesley T2, Champarnaud E3, Mussell C3, Harter L4, Calton L4, McKeown D5. 1Waters Corporation, 34 Maple Street, Milford, MA 01757. 2The University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109. 3Chemical Measurement and Calibration, LGC Limited, Teddington, TW11 0LY, UK. 4Waters Corporation, Atlas Park, Simonsway, Manchester, M22 5PP, UK. 5Analytical Services International Ltd, London, SW17 0RE, UK.

HPLC DETERMINATION OF VANCOMYCIN AND ITS CRYSTALLINE DEGRADATION PRODUCTS RELEASED FROM BONE GRAFTS
Klapkova E1, Prusa R1, Melichercik P2. 1Department of Medical Chemistry and Clinical Biochemistry, Charles University 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic. 2Department of Orthopaedics, Charles University 1st Faculty of Medicine and University Hospital Motol, Prague, Czech Republic.

MULTICENTER METHOD EVALUATION OF THE ARK™ METHOTREXATE IMMUNOASSAY.
Godefroid M1, von Meyer A2, Parsch H3, Streichert T4, Verstraete AG1, Stove V1. 1Laboratory of Clinical Biology, Ghent University Hospital and Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium. 2Städtisches Klinikum München GmbH, Department Klinische Chemie, Munich, Germany. 3Central Laboratory, University Hospital Erlangen, Germany. 4Zentrallaboratorien Universitätsklinikum Eppendorf, Institut für Klinische Chemie, Hamburg, Germany.

QMS® EVEROLIMUS IMMUNOASSAY – TDM FOR KIDNEY, HEART AND LIVER TRANSPLANT PATIENTS RECEIVING EVEROLIMUS THERAPY.
Yokobata K, Cheung C, Lee C, Arabshahi L, Li, H. Clinical Diagnostics Division, Thermo Fisher Scientific, Fremont, CA, USA.

SIMULTANEOUS MEASUREMENT OF IRINOTECAN AND ITS METABOLITES IN HUMAN PLASMA BY HPLC WITH FLUORESCENCE DETECTION .
Shibasaki-Hirano H1, Minowa Y1, Ayukawa H1, Yokokawa A1, Hosoda K2, Ishii K2, Nagashima F3, Furuse J3, Furuta T1. 1Tokyo University of Pharmacy and Life Sciences, School of Pharmacy 2Kyorin University School of Health Sciences. 3Kyorin University School of Medicine.

LC-MS/MS METHOD FOR THE QUANTIFICATION OF INFLIXIMAB IN HUMAN BLOOD.
H. Nakamura, T. Araki, T. Nakamura, K. Yamamoto. Department of Clinical Pharmacology, Gunma University Graduate School of Medicine, Maebashi, Japan. Department of Pharmacy, Gunma University Hospital, Maebashi, Japan.

PHARMACOGENETICS ALGORITHMS FOR INDIVIDUALIZING WARFARIN DOSING: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS.
Hui-Lin Tang1, Xiao-Guang Li1, Ting Zhang1, Hong-Guang Xie2, Suo-Di Zhai1. 1Department of Pharmacy, Peking University Therapeutic Drug Monitoring and Clinical Toxicology Center, Peking University Third Hospital, Beijing, China. 2General Clinical Research Center and Division of Clinical Pharmacology, Nanjing Medical University Nanjing First Hospital, Nanjing, China.

DETERMINATION OF RIBAVIRIN IN HUMAN PLASMA BY LC-MS/MS.
Östervall J1, Östlund A1, Pohanka A2. 1Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden. 2Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

A HIGHLY SELECTIVE, ROBUST AND SIMPLE ACCURATE MASS MS/MS DRUG SCREENING METHOD USING THE TRIPLETOF® 5600+ SYSTEM.
Seegmiller J.1, Moshin J.1 , Taylor A.M.2 and Jarvis M.J.Y.2. 1AB SCIEX, 353 Hatch Drive, Foster City, CA. 2AB SCIEX, 71 Four Valley Drive, Concord, ON, Canada, L4K 4V8.

APPLICATION OF ULTRA HIGH LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY TO THE ANALYSIS OF THREE ATYPICAL ANTIPSYCHOTICS AND ONE ANTIDEPRESSANT: RISPERIDONE ,9-OH RISPERIDONE, ARIPIPRAZOLE ,DEHYDRO-ARIPIPRAZOLE, ZIPRASIDONE, VENLAFAXINE AND O-DESMETHYL-VENLAFAXINE (ODES) IN SERUM AND PLASMA.
Juenke J.M.1, Brown P.I.1, and Johnson-Davis K.L.1,2. 1ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT. 2Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT.

EFFECT OF BREAST CANCER RESISTANCE PROTEIN ON CIMETIDINE TRANSPORT ACROSS THE PLACENTAL MODEL USING DIFFERENTIATING HUMAN CHORIOCARCINOMA JEG-3 CELLS.
K. Ikeda, C. Ueda, Y. Yagi, H. Ogura, S. Kawanishi, Y. Hatsuda, S. Nishii and M. Ogawa. Laboratory of Practical Pharmacy and Pharmaceutical Care, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.

DETERMINATION OF WARFARIN IN HUMAN PLASMA BY UPLC AND ITS CLINICAL APPLICATION.
Yuangao Zou, Hong Jiang, Yi Li, Yun Liao, Jie Chen, Lanlan Wang. Department of Laboratory Medicine, West China Hospital of Sichuan University, Sichuan Province, People’s Republic of China. Co-Corresponding authors: Lanlan Wang , Prof. Email: wanglanlan999@163.com.

VALIDATION OF AN LC/UV METHOD FOR PIPERACILLIN/TAZOBACTAM MONITORING IN CRITICALLY ILL PATIENTS.
Zufía L, Aquerreta I. Aldaz A. Pharmacy Department, Clínica Universidad de Navarra, c/ Pío XII 36, 31008 Pamplona, Spain.

VALIDATION OF AN LC/UV METHOD BASED ON ACCURACY PROFILES FOR DAILY 5-FLUOROURACIL DOSE ADJUSTMENT IN CANCER PATIENTS.
Zufía L, Egües A, Aldaz A. Pharmacy Department, Clínica Universidad de Navarra, c/ Pío XII 36, 31008 Pamplona, Spain.

MULTIELEMENT DETERMINATION OF K, Ca, Mg, Li, Cu, Zn, Rb, Fe, B, P, and Si IN BIOLOGICAL MATRICES USING SIMULTANEOUS INDUCTIVELY COUPLED PLASMA OPTICAL EMISSION (ICP-OES) DETECTION.
Blum LM, Rieders NF, Fucskó J. NMS Labs, Willow Grove, PA 19090.

EVALUATING THE URINE MATRIX EFFECTS IN LC-MS/MS ANALYSIS FOLLOWING FILTRATION FOR PAIN MANAGEMENT COMPOUNDS.
Marc J. Rumpler, Lindsay A. L. Bazydlo, Timothy J. Garrett, Bruce A. Goldberger
Department of Pathology, College of Medicine, University of Florida, Gainesville, Florida.

DEVELOPMENT, DESIGN AND VALIDATION OF AN LC-MS/MS METHOD FOR MORPHINE AND METABOLITES IN HUMAN PLASMA: FOCUS ON MATRIX EFFECTS USING STRAIGHT PHASE CHROMATOGRAPHY.
Andersson M, Bjorkhem-Bergman L and Beck O. Department of Laboratory Medicine, division of Clinical Pharmacology, Karolinska Institute and University Hospital, Stockholm, Sweden.

COMPREHENSIVE TOXICOLOGICAL SCREENING USING GENERIC MS/MSALL ACQUISITION ON A Q-TOF TANDEM MASS SPECTROMETER.
Jarvis M.1, Seegmiller J.2, Moshin J.2 and Taylor A.1. 1AB SCIEX, Concord, Canada; 2AB SCIEX, Foster City, USA.

PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF MYCOPHENOLIC ACID IN de novo KIDNEY TRANSPLANT PATIENTS.
Minh Thuan Nguyen Thi, Michel Mourad, Arnaud Capron, Flora Musuamba Tshinanu, Marie-Françoise Vincent, Pierre Wallemacq. Université catholique de Louvain, Louvain center for Toxicology and Applied Pharmacology (LTAP), Brussels.

EVALUATION OF THE NOVEL ELECSYS CYCLOSPORINE A ASSAY COMPARED TO LC-MS/MS, ABBOTT ARCHITECT AND SIEMENS DIMENSION.
Verstraete A.1, Shipkova M.2, Wallemacq, P.3, Vogeser M.4, Alía P.5,Widmann M.6. 1Gent University Hospital, Belgium; 2Katharinenhospital, Stuttgart, Germany; 3Clinique Universitaire St. Luc, Belgium; 4Klinikum der Universität München, LMU, Germany; 5Hospital Universitari de Bellvitge, Spain; 6Roche Diagnostics GmbH Mannheim, Germany.

ARK™ HOMOGENEOUS ENZYME IMMUNOASSAYS FOR VORICONAZOLE AND POSACONAZOLE.
Oh, S., Moon, B., Valdez, J. ARK Diagnostics, Inc., Fremont, CA.

INFLUENCE OF MESALAZINE ON THIOPURINE S-METHYLTRANSFERASE ACTIVITY.
Outeda-Macías M, Salvador-Garrido P, Martínez-López LM, Martín-Herranz I. Pharmacy Service. University Hospital of A Coruña. Xerencia de Xestión Integrada A Coruña. A Coruña. Spain.

EVALUATION OF LEVETIRACETAM ARKTM ASSAY ON THE ABBOTT ARCHITECTTM ANALYSER.
Outeda-Macías M, Salvador-Garrido P, Martínez-López LM, Martín-Herranz I. Pharmacy Service. University Hospital of A Coruña. Xerencia de Xestión Integrada A Coruña. A Coruña. Spain.

A TACROLIMUS METHOD COMPARISON BETWEEN QMS(R) PERFORMED IN A INDIKO ANALYZER AND LC-MS/MS IN RENAL AND LIVER TRANSPLANT PATIENTS.
Más-Serrano P. Hospital General Universitario de Alicante. Clinical Pharmacokinetic Unit. Pharmacy Department. Hospital General Universitario de Alicante (Alicante, Spain). Authors: Más-Serrano P, Pastor C, Nalda-Molina R, Ramón-López A, Palacios E, García R, Rodríguez-Laiz G, Lluis F, Selva J. Institutional affiliations: Pharmacy Department and Surgical Department from Hospital General Universitario de Alicante (Alicante, Spain). División de Farmacia y Tecnología Farmacéutica. Universidad Miguel Hernández (Elche, Spain)

SIMPLE HPLC-UV METHOD FOR MYCOPHENOLIC ACID (MPA) MONITORING IN PLASMA
Kunicki P.K., Boczek A., Waś J. Clinical Pharmacology Unit, Institute of Cardiology, Warsaw, Poland.

UPLC-MS/MS METHOD APPLIED FOR THE ANALYSIS OF 4 PRIMARY IMMUNOSUPPRESSIVE AGENTS IN PATIENTS’ SAMPLES
Kunicki P.K., Boczek A., Waś J. Clinical Pharmacology Unit, Institute of Cardiology, Warsaw, Poland.

PRACTICAL APPROACH OF NEW LC-MS/MS METHOD FOR MONITORING TACROLIMUS IN WHOLE BLOOD OF PATIENTS AFTER KIDNEY TRANSPLANTATION.
Bodnar-Broniarczyk M1, Czaplicka K1, Pawinski T1, Majchrzak J2, Durlik M2. 1Department of Drug Chemistry, Medical University of Warsaw, Warsaw, Poland. 2Department of Transplantation Medicine and Nephrology, Medical University of Warsaw, Warsaw, Poland.

PERFORMANCE OF A NEW IMMUNOASSAY TO MEASURE TACROLIMUS.
Holt D1, Moreton-Clack M1, Hayward V1, Dickson L1, Johnston A1 and Wallemacq P2. 1Analytical Services International, St George’s University of London, London, UK. 2Laboratory of Analytical Biochemistry, University Hospital St Luc, Brussels, BELGIUM.

MERCURY AMNESIA: A SIMPLE AND ROBUST MERCURY WHOLE BLOOD ASSAY USING INDUCTIVELY COUPLED PLASMA – MASS SPECTROMETRY (ICP-MS) WITHOUT MEMORY EFFECTS
Parker R.1, Haglock C.J.2, Strathmann F.G.2,3. 1ARUP Laboratories, Salt Lake City, UT; 2ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT; 3University of Utah, Department of Pathology, Salt Lake City, UT.

ASSAY OF THE THIOPURINE NUCLEOTIDES FOR TDM USING HPLC-MS/MS COMPARED TO HPLC-UV IN WHOLE BLOOD.
Norris R1,2,3, Duley J1,3, Esmail L1,3, George R1, Florin T1,4. 1Mater Pathology & Mater Medical Research Institute, South Brisbane, Australia. 2School of Pharmacy Griffith University, Gold Coast, Australia. 3School of Pharmacy, University of Queensland, PACE, Woolloongabba, Australia. 4Department of Medicine, The University of Queensland, St Lucia, QLD.

SIMULTANEOUS DETERMINATION OF CISPLATIN, HYDROXO COMPLEXES, AND OH-DIMER USING HPLC.
Ryuji Kato1, Takaji Sato2, Shoichi Yoshikai1, Kyohei Ogawa1, Takahiro Ogawa1, Daiki Kobata1, Kazuhiko Tanaka3, Yoshio Ijiri1, Tetsuya Hayashi1. 1Laboratory of Cardiovascular Pharmacotherapy and Toxicology, Osaka University of Pharmaceutical Sciences. 2Laboratory of Analytical Chemistry, Osaka University of Pharmaceutical Sciences. 3 Kidney Center, Shirasagi Hospital.

EVALUATION OF THE CHROMSYSTEMS® IMMUNOSUPPRESSANTS KIT ON AN ALLIANCE/QUATTRO PREMIER XE SYSTEM AND COMPARISON OF CYCLOSPORINE A (CSA), TACROLIMUS (TAC) AND EVEROLIMUS (EVR) BLOOD CONCENTRATIONS WITH WATERS® MASSTRACK KIT AND IMMUNOASSAY IN TRANSPLANTED PATIENTS.
Flornoy A, Villard C, Lacarelle B, Sampol-Manos E. Pharmacokinetic and Toxicology Department, Timone Hospital, Marseille, France.

ANALYSIS OF SERUM FROM TRAUMATIC BRAIN INJURY PATIENTS BY A HIGH RESOLUTION MASS SPECTROMETRY COMPREHENSIVE DRUG SCREEN.
Shugarts S.B., Thoren K, Lynch K.L., Wu AHB. Department of Laboratory Medicine, University of California, San Francisco and San Francisco General Hospital, CA 94110.

A NEW DETERMINATION METHOD OF EPOXYEICOSATRIENOIC AND DIHYDROXYEICOSATRIENOIC ACIDS BY LC-MS/MS.
Toda T1, Mukai Y1, Takeuchi S1, Senda A1, Hayakawa T1, Inotsume N1, Rane A2, Eliasson E2. 1Hokkaido Pharmaceutical University School of Pharmacy; 2Karolinska Instututet.

EFFECT OF HEMOLYSIS, ICTERUS, AND LIPEMIA ON THREE ACETAMINOPHEN ASSAYS.
Zhang, Y., Kwong, T., Kellogg, M. University of Rochester Medical Center, Rochester, NY 14618, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115.

QMS TEICOPLANIN SERUM IMMUNOASSAY PERFORMANCE ON THE THERMO SCIENTIFIC INDIKO PLUSAND COMPARISON TO FLUORESCENCE POLARIZATION IMMUNOASSAY.
De Sloovere M.M.W., Verstraete A.G., Hollebosch M., Van Caeneghem E., Stove V.. Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.

ADAPTATION OF URINE CEDIA BENZODIAZEPINE AND BARBITURATE ASSAYS FOR THE ANALYSIS IN SERUM AND EVALUATION OF DRI TRICYCLIC SERUM TOX ASSAY ON THE THERMO SCIENTIFIC INDIKO PLUS
De Sloovere M.M.W., Stove V., Hollebosch M., Van Caeneghem E., Verstraete A.G. Department of Laboratory Medicine, Ghent University Hospital, Ghent, Belgium.